Limoneira (LMNR) just posted Q2 2026 results with revenue of US$23.9 million and a basic EPS loss of US$1.20, alongside net income excluding extra items of a US$21.5 million loss. Over recent quarters the company has seen revenue move from US$35.1 million in Q2 2025 to US$23.9 million in Q2 2026, with basic EPS shifting from a loss of US$0.20 to a loss of US$1.20. Those trends keep the spotlight firmly on cost control and overall margins. The latest print leaves investors weighing modest trailing revenue growth against pressure on profitability and margins that remain under strain.
See our full analysis for Limoneira.With the headline numbers on the table, the next step is to set these results against the most common narratives around Limoneira to see which storylines hold up and which are challenged by the data.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Losses on a TTM basis reach US$40.9 million
- On a trailing 12 month view to Q2 2026, Limoneira reported total revenue of US$132.4 million and a net loss excluding extra items of US$40.9 million, compared with a net loss of US$2.3 million on revenue of US$176.6 million in the trailing period ending Q2 2025.
- Consensus narrative points to revenue of US$122.7 million and earnings of US$7.3 million by 2028, yet the recent trailing 12 month pattern shows revenue at US$132.4 million alongside a loss of US$40.9 million, which sits quite far from the earnings level analysts are using in that narrative.
- Over the last five trailing 12 month snapshots provided, revenue moved from US$186.1 million to US$132.4 million, while net income excluding extra items shifted from a profit of US$7.6 million to a loss of US$40.9 million. As a result, the path toward the positive 6.0% margin discussed in the consensus view is not yet visible in these figures.
- Analysts in the consensus narrative are also assuming earnings recovery strong enough to support an 80.6x P/E on US$7.3 million of earnings. However, the current data still shows losses on both a quarterly and trailing 12 month basis, which leaves that valuation assumption entirely dependent on future margin improvement rather than anything in the recent results.
Q2 loss of US$21.5 million deepens recent EPS pressure
- For Q2 2026, the company reported a net loss excluding extra items of US$21.5 million and a basic EPS loss of US$1.20, compared with a basic EPS loss of US$0.53 and a net loss of US$9.6 million in Q1 2026.
- Bears highlight long running earnings pressure and widening losses, and the quarterly numbers align with that concern, as the loss excluding extra items in the last four reported quarters moved from US$3.2 million in Q1 2025 to US$21.5 million in Q2 2026 while basic EPS over the same stretch moved from a loss of US$0.18 to a loss of US$1.20.
- The risk summary also notes that losses have expanded at about a 29.9% annual rate over five years, which is consistent with the step up in quarterly losses in the data, and ties directly into bearish worries about long term earnings resilience even as certain partnerships and real estate projects are discussed as offsets.
- Given that forecasts in the supplied data indicate expectations for continued unprofitability over the next three years, the current Q2 loss of US$21.5 million does not contradict the bearish narrative that heavy reliance on lemons, avocados and real estate leaves the company exposed to swings in revenue and ongoing cost pressure.
Mixed valuation signals at US$13.18 share price
- At a share price of US$13.18, Limoneira is trading at a cited P/S of 1.8x compared with 0.8x for the wider US Food industry and 5.3x for peers, while the provided DCF fair value of US$0.61 sits well below the current price and the only allowed analyst price target from the instructions is US$21.33.
- Consensus narrative talks about analysts targeting higher prices based on future margin improvement, yet the combination of a DCF fair value of US$0.61, an only allowed analyst target of US$21.33, and current trailing 12 month losses of US$40.9 million means valuation signals pull in different directions and rely heavily on views about how quickly losses can narrow.
- The risk summary also notes that debt is not well covered by operating cash flow and that a 2.28% dividend yield is not covered by earnings or free cash flow, which adds balance sheet and income risk to any valuation case that leans on future earnings recovery.
- At the same time, revenue growth quoted at 7.4% per year on a trailing basis and a P/S that is lower than the 5.3x peer average are what supporters of the consensus narrative may point to, even though that growth rate is expected to be slower than the 11.9% per year cited for the broader US market.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Limoneira on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If this mix of pressure and potential feels conflicting, that is exactly why it is worth checking the numbers yourself and moving quickly to shape your own view. To understand what could go wrong before you commit fresh capital, start with the 2 important warning signs.
See What Else Is Out There
Limoneira is wrestling with widening losses, uncovered dividends, and pressure on margins, which all raise questions about earnings resilience and balance sheet strength.
If you want ideas that lean more on financial resilience than on a turnaround story, check out solid balance sheet and fundamentals stocks screener (47 results) to find companies with sturdier foundations and clearer coverage of obligations.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com